1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
38 
recombinant DNA, as defined in section 1821(a)(2), 
which would lead to greater 'protection of researchers, 
the public, and the environment or would further the 
purposes of the Recombinant DNA Safety Regulation 
Act, and its recommendations with regard thereto; 
“(8) appropriate additional recommendations for 
the conduct of recombinant DNA activities particularly 
with respect to the best approaches for assuring the safest 
and most appropriate applications and uses of recom- 
binant DNA and the appropriate role of assessment of 
risk-benefit criteria in these determinations; 
“( 9) a determination of the status and extent of 
recombinant DNA activities conducted in exempted 
areas in the United States and in areas outside the 
United States, and an analysis of the nature of regula- 
tion in other countries; 
“(10) a summary of the Commission's decisioris 
with respect to the facilities which have been licensed and 
the terms and conditions attached thereto; and 
“(11) a summary of actions taken to accomplish the 
purposes of the Recombinant DNA Safety Regulation 
Act, the nature of the difficulties encountered in enforce- 
ment, the number and nature of penalties imposed during 
the preceding year and an evaluation of their adequacy 
as deterrants to future violations, areas of recombinant 
[ 708 ] 
